Sanofi (NASDAQ:SNY) Rating Increased to Strong-Buy at Hsbc Global Res

Sanofi (NASDAQ:SNY) was upgraded by analysts at Hsbc Global Res to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Other analysts have also issued research reports about the company. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. The Goldman Sachs Group assumed coverage on shares of Sanofi in a research note on Friday, March 21st. They set a “neutral” rating and a $65.00 price objective on the stock. Finally, BNP Paribas began coverage on shares of Sanofi in a research note on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 target price for the company. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $63.33.

Sanofi Stock Performance

NASDAQ:SNY opened at $54.95 on Monday. The firm has a market capitalization of $138.82 billion, a PE ratio of 22.07, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. Sanofi has a 12 month low of $45.80 and a 12 month high of $60.12. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The business’s fifty day moving average price is $54.51 and its 200 day moving average price is $52.07.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.04. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The business had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. During the same quarter in the prior year, the firm earned $1.78 earnings per share. The business’s quarterly revenue was down 11.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Institutional Trading of Sanofi

Several hedge funds have recently made changes to their positions in SNY. Invesco Ltd. grew its stake in shares of Sanofi by 3.5% in the fourth quarter. Invesco Ltd. now owns 12,059,283 shares of the company’s stock worth $581,619,000 after purchasing an additional 408,752 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Sanofi by 3.8% in the 4th quarter. Bank of America Corp DE now owns 12,017,140 shares of the company’s stock valued at $579,587,000 after purchasing an additional 441,637 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Sanofi by 88.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company’s stock valued at $522,991,000 after acquiring an additional 5,091,304 shares during the period. Boston Partners boosted its stake in Sanofi by 86.4% in the 4th quarter. Boston Partners now owns 5,396,531 shares of the company’s stock worth $260,607,000 after purchasing an additional 2,501,073 shares during the period. Finally, Franklin Resources Inc. raised its stake in Sanofi by 10.8% during the 4th quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company’s stock valued at $182,164,000 after purchasing an additional 369,530 shares during the period. Institutional investors own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.